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Abstract
Purpose of Review Liver stem cells have been proposed as alternatives or additions for whole liver transplantations to accom-
modate the donor liver shortage. Various sources of liver stem cells have been described in experimental animal studies. Here we
aim to compare the various studies.
Recent Findings Irrespective of the experimental design, the percentage of long-lasting survival and functional recovery of
transplanted cells is generally very low. An exception to this are the proliferating hepatocytes transplanted into Fah(-/-) Rag2−/
−IL2rg−/−mice; here 4-month post-transplantation around 65% repopulationwas observed, and 11/14mice survived in contrast to
zero survival in sham-treated animals.
Summary Taking the different cellular sources for the organoids, the different maturation status of the transplanted cells, and the
variable animal models into account, a paper-to-paper comparison is compromised. This lack of objective comparison restricts
the translation of these model studies into clinical practice.
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Introduction
The liver, in weight one of the body’s largest organs, has
a crucial role in a plethora of biological functions.
Among these are functions associated with lipid metabo-
lism (energy storage), ammonium removal, bile acid syn-
thesis, and the production of clotting factors and
(de)toxification of compounds delivered to the liver via
the intestinal tract. Not to mention liver-specific viruses,
but the liver is continuously exposed to toxins and drugs
and especially in the well-fed Western World with high
levels of lipids [1]. Although the liver has an enormous
regenerative capacity, the insults can be too severe for
the liver regeneration potential. Reviews on the mecha-
nism of liver regeneration are numerous, including dis-
cussions on the various flavors of liver stem cells in-
volved in the daily tear-and-wear on the recovery from
more severe incidental insults (e.g. [2–7].). Recently, in-
numerous reviews on organoids as translational models
and for developmental studies have been published (e.g.,
[8–14].).
This review focusses on the potential of liver organoids to
be used as alternatives for liver transplantation. Organoids for
disease modeling and or improved toxicology models are not
addressed here. The readers will realize that the term organoid
and the cell types constituting an organoid are currently far
from clear-cut. Therefore, emphasis in this review is on the
various types of liver organoid transplantations described to-
day and current hurdles hampering the clinical application of
transplantable liver organoids as alternatives for whole liver
transplantations.
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The Start
Due to the lack of suitable organs for liver transplantation,
around 25% of the patients on the waiting list for whole liver
transplantation die before they receive a matching donor liver
[1, 15]. The percentage of successful transplantations is high,
but lifelong immunosuppression and the costs associated here-
with are enormous [16, 17]. Moreover, it is anticipated that the
number of people requiring liver transplantation is likely to
increase in the next decades in view of the long-term detri-
mental effects of especially HBV and the increase in people
suffering from the deleterious effects of obesity on the liver
function, especially if the nonalcoholic fatty liver disease
(NAFLD) progresses into nonalcoholic steatohepatitis
(NASH) [18]. Undoubtedly, alternatives for whole liver trans-
plantation are therefore urgently needed.
The recent advances in liver organoid culture open novel
alternative pathways. Organoids are most often defined as an
in vitro 3D-multicellular cluster derived from stem/progenitor
cells, capable of self-renewal and self-organization, that reca-
pitulates the function of the tissue from which it was derived
[19, 20]. These functional, not necessarily architectural, mini-
organs have been described initially for the intestine [21], not
surprisingly in view of the enormous turnover of the intestine.
In 2013 a landmark paper first described mouse liver
organoids derived from single Leucine-rich repeat-containing
G protein coupled receptor 5+ (Lgr5, G-receptor coupled re-
ceptor 49) liver stem cells [22••]. Lgr5, and its homologs Lgr4
and Lgr6, are receptors for R-spondin, which upon binding of
R-spondin inactivate the E3 ligases Znrf3 and Rnf43. This, in
turn, results in an increased concentration of theWnt receptors
Frizzled and Lrp5/6 on the cell surface and a high activation of
the canonical Wnt/beta-catenin signaling pathway. Single
Lgr5+ cells, isolated by means of FACS, can initiate organoid
formation in vitro, which can be expanded in culture under
growth conditions with active Wnt signaling and can be driv-
en into a hepatocyte-like phenotype under differentiation con-
ditions. Moreover, it turned out that functional hepatocytes
could be generated upon transplantation of clonally expanded
organoids in fumarylacetoacetate hydrolase Fah(-/-) mice, a
model for severe liver damage. In the following years, liver
organoids from humans and other non-primate mammals were
described [23–26]. The cells from these 3D culture systems
were applied in liver transplantations, disease modeling, and
liver developmental studies. Under expansion conditions,
these cells were proliferating in culture for over 8 months
while remaining genetically stable as assayed by means of
whole genome sequencing and/or karyotyping [23, 24, 26].
This suggests that the organoids are not likely to form tumors
in vivo, and therefore the genetic stability fulfilled a require-
ment for transplantation.
Of note, organoids derived from Lgr5+ stem cells are pure
epithelial structures. In contrast, the liver consists of various
cell types in order to perform its multiple functions: hepato-
cytes (biotransformation, coagulation factors) account for
about 60–70% of the cells, whereas other cell types are less
abundant, e.g., stellate cells (vitamin A storage, 5–8%),
Kupffer cells (liver macrophages, 10–15%), cholangiocytes
(bile duct cells, 3–5%), and liver sinusoidal endothelial cells
(blood vessel lining, 15–20%). This cellular variability poses
pressure on the use of the word “organoid” for
stem/progenitor-derived 3D liver cultures, since those
“organoids” do not self-organize into a structural entity con-
stituting the various (non-epithelial) liver cells types.
However, for the sake of simplicity, the term “organoids” in
the following applies to 3D stem/progenitor-derived in vitro
cultures mimicking to a certain degree some aspects of the
livers function.
Transplantation with Liver Organoids
The first description of transplanted liver organoids, expanded
mouse Lgr5+ cells from liver ductal origin into Fah(-/-) Rag(-/
-) IL2rg(-/-) mice, revealed that as little as in 3 out of 5 mice,
some Alb+/Fah+/CYP+ cell clusters were detected 2–
3 months post-transplantation. These cells accounted for
around 0.1–1% of the total liver volume [22••]. A few years
later, transplantation of human liver organoids into retrorsine/
CCl4-treated Balbc/nude mice [23] and rat liver organoids
into Fah(-/-) IL2rg(-/-) rats [25] has been described.
Although the successful recovery from induced liver damage
was obtained in 2 out of 6 mice and 7 out of 11 rats in those
studies, again only a few % reconstitution of the liver volume
was achieved. One positive exception was observed in 1 rat,
where almost 20% of the liver volume was repopulated by
donor cells [25].
In addition to lgr5+-derived organoids, the cellular basis of
liver organoids can also arise from induced pluripotent stem
cells (iPSs) that are differentiated toward hepatocyte- or
cholangiocyte-like cells. In this respect, the findings by
Takebe and co-workers are of great interest [27••, 28]. In con-
trast to the above-mentioned Lgr5+ adult stem cells, the iPS-
derived hepatocyte-like organoids self-organized into 3D-
multicellular structures on the basis of a mixture of iPS cells
(or fetal derived hepatocyte-like cells) in combination with
HUVECs and MSCs. Upon transplantation of these buds into
immunodeficient NOD/SCID mice, functional hepatocyte
cords were formed lining with the sinusoidal endothelium.
Most strikingly here was the connectionwith the blood system
of the recipient mice.
The cellular source of transplantable liver cells is even
more widespread, and then Lgr5+ and iPSCs derived donor
cells only. For instance, extrahepatic cholangiocytes can be
the origin of the cells in a transplanted organoid [29]. Here a
damaged bile duct epithelium is reconstituted under the kid-
ney capsule by transplantation of organoids from extrahepatic
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cholangiocytes in NSG-mice [29]. The choice here for this cell
type makes sense in view of the damaged target organ to be
addressed with the transplantation.
Transplantations with Hepatocytes
from Non-adult-Hepatocyte Sources
Taking into consideration the damaged cell types of specific
liver diseases, it is conceivable that hepatocytes are at the basis
of transplantation to recover damaged hepatocytes. Therefore,
iHEPS (directly reprogrammed hepatocytes) were differenti-
ated toward hepatocytes including CYP activity [30]. In com-
bination with a PCL scaffold, the differentiated iHEPS nor-
malized ALTand bilirubin levels in Fah(-/-) Rag2(-/-) IL2rg(-/
-) mice, whereas AST levels remained elevated [30]. This is
indicative of a partial recovery from the liver damage by the
transplanted cells.
Yet another cellular source was utilized by Hu et al. [31],
who compared transplantation efficiency of fetal hepatocyte-
derived organoids with pediatric primary hepatocyte
organoids [31]. Three-month post-transplantation in Fah(-/-)
Rag2(-/-) NOD IL2rg(-/-) mice nodules of Alb+/MRP2+/
Cyp2E1+ cells were still detected. Furthermore, the prolifera-
tion marker Ki67 indicated that these cells were actively pro-
liferating. The albumin secretion was slightly better in the
pediatric compared to the fetal-derived organoids.
Massive cell proliferation was achieved upon TNF alpha
stimulation of mouse bile duct-derived hepatocytes [32]. In
the Fah (-/-) mice classical model for liver cell transplantation,
3–4 months post-transplantation revealed only a few percent-
ages of repopulated cells that were Ki67+ positive. A very
high repopulation was observed in Fah(-/-) Rag2(-/-)
IL2rg(-/-) mice transplanted with bi-potent proliferating hepa-
tocytes [33]. Not only the authors showed a way to reach
enormous cell numbers but the transplantation results were
impressive. Eleven out of 14mice survived (in contrast to zero
in the sham-operated mice), and on average 65% of repopu-
lation of the recipient liver was achieved.
One of the very few studies in rats was a transplantation of
iPS-derived hepatic stem cells into Gunn rats, the classical
model for the Crigler-Najjar syndrome [34]. Upon maturation
of the transplanted stem cells in the recipient Gunn rats,
hyperbilirubinemia was severely reduced (about one third),
and human uridine diphosphate glucuronosyltransferase 1
family polypeptide A1 (UGT1A1) expressing cells were de-
tected in less than 1% of the cells.
The Misty Road
Taking the results of all these studies, it is obvious that a
comparison of the various studies is difficult. In view of the
different cellular sources for the organoids, different matura-
tion status of the transplanted cells, variable animal models,
and biological parameters described, a paper-to-paper com-
parison is hampered. A summary of the various organoid
transplantation studies is presented in Table 1. Recently trans-
plantation studies were performed with autologous and gene-
corrected canine livers organoids in COMMD1-deficient dogs
[35]. Due to a large deletion encompassing exon-2 of the
COMMD1-gene [36], these dogs develop copper toxicosis,
at higher speed and more pronounced as compared to for
instance Wilson disease [37];[38]). Preliminary data point in
the same direction as for the rodent models, with the engraft-
ment of donor cells being ineffective on the long run. In the
model of inherited copper toxicosis, the follow-up period was
up to 2 years post-transplantation.
One obvious drawback of these initial studies was the cel-
lular composition of these organoids. They consisted mainly
of partially differentiated hepatic epithelial cells (at best cov-
ering a limited array of hepatocyte functions, e.g., albumin
production and a few biotransformation enzymes). The cellu-
lar heterogeneity and architecture of the liver were not taken
into account, as was the possible heterogeneity in hepatocyte-
like cells within one organoid (or between organoids of same
donor, not to mention variations between donors). On top of
this, various research groups developing liver organoids used
different sources to acquire organoids consisting of hepatocyte
(or cholangiocyte) like cells. This makes the road toward suc-
cessful organoid transplantations quite challenging.
The Next Hurdle Toward the Finish
Mathematically speaking, the most cost-effective means to
overcome organ shortage is related to lifestyle changes (pre-
vention of liver diseases) and the stimulation to acquire more
donor organs [39]. Although cost-effective in theory and in
view of the highly effective current HCV-treatment regimens
improvements are expected, donor shortage will remain an
obstacle in the years to come.
Therefore, alternatives for whole liver transplantations will
be needed as urgently as before. So what hampers clinical ap-
plication of organoids as alternatives for whole liver transplan-
tations? The culture of organoids most often requires undefined
Matrigel, a compound extracted from the Engelbreth-Holm-
Swarm (EHS) mouse sarcoma. Apart from ethical concerns
related to the usage of mice for the production of Matrigel,
the variable functionality and the largely unknown and possibly
variable constitution of Matrigel clearly block FDA approval.
Therefore, it is of the utmost importance to investigate a more
robust, defined, and animal-free alternatives for Matrigel. This
is a highly competitive field of biotechnology nowadays. In
order to make all the claims on “highly potential” alternatives
for Matrigel for liver organoid culture comparable with each
other, some guidelines regarding liver functionality are re-
quired, if not urgently needed. These guidelines should include,
among other parameters, a minimal list of defined
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characteristics of a functional hepatocyte, a functional
cholangiocyte, or other liver cell types to be included in the
organoid system. As long as such guidelines are not implement-
ed, the field of Matrigel alternatives remains open for “wild
claims.” Even more difficult is the issue of cellular heterogene-
ity within one organoid and between organoids of the same
donor. This heterogeneity was clearly described in human
iPS-derived organoids bymeans of single cell RNA-Seq, which
revealed several cell clusters related to the various cell types
harbored in the organoids such as hepatocyte-, stellate-, and
Kupffer-like cells [40••]. Even within the large hepatocyte-
like cell clusters, an enormous variation in RNA expression
was observed. This multicell-type organoid provided a novel
approach to study liver fibrosis, especially with the incorpora-
tion of atomic force microscopy to evaluate the stiffness of the
organoids as a measure for fibrogenesis. For other types of
organoids, the heterogeneity of the cells within an organoid is
not yet fully appreciated and opens new lines of research. For
instance, after disrupting an organoid, does it reconstitute in the
same 3D cellular makeup as before or is reorganization of an
organoid a random process? In addition to the variations be-
tween organoid types, there is also a lack of means to compare
the various transplantation studies with each other. ISSCR
guidelines exist for stem cell research and clinical translation
(https://www.isscr.org/membership/policy/2016-guidelines/
guidelines-for-stem-cell-research-and-clinical-translation).
This, however, has not cultivated a paper-to-paper comparison
and improved the clear repetition of an experiment. For RT-
qPCR, this problemwas addressed by theMIQE-precise guide-
lines, nowadays obligatory for numerous scientific journals,
providing a checklist with minimal requirements needed for
proper comparison and repetition [41]. Based on the success
of the MIQE-precise guidelines, an initiative to make some-
thing similar for organoid transplantation studies is provided
in Table 2. The required information is presented in the studies
discussed above although a paper-to-paper comparison is diffi-
cult in view of the various measurements. A checklist would


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2 Key criteria on
the most essential
information needed for
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comparison and reproducibility of the described studies. This is
beneficial for reviewers, readers, and those who want to repeat/
continue on the published papers.
The authors remain positive about the future of transplant-
able liver organoids. Different approaches are already ongoing
in that respect, varying from developments with decellularized
liver scaffolds [42•, 43–45, 46•], organoid cultures combined
with bioprinting, upscaling and improved differentiation pro-
tocols [31–33, 47]; (Schneeberger et al., accepted), more and
better predictive animal models (e.g., [35]), and so forth.
Those combined efforts all seem to pave the way for trans-
plantable liver organoids. But yet unknown hurdles are to be
expected (“the known unknowns”), including ethical issues
[48], as always in the translation of models into clinical prac-
tice. These prospects keep us motivated as never before.
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